Spark Therapeutics Announces Multiple Presentations on Updated Hemophilia A and Hemophilia B Phase 1/2 Clinical Trials at 59t...
December 05 2017 - 7:30AM
Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy
company dedicated to challenging the inevitability of genetic
disease, today announced that Lindsey A. George, M.D., attending
physician in the Division of Hematology at Children’s Hospital of
Philadelphia, will present data on the company’s hemophilia A and B
investigational gene therapies at the 59th American Society of
Hematology (ASH) Annual Meeting and Exposition at the Georgia World
Congress Center in Atlanta.
Dr. George will be presenting twice on Monday, Dec. 11, during
the “Gene Therapy and Transfer: Gene Therapy for Hemophilia and
Improving Lentiviral Vectors” session, to be held in auditorium
C101, on level 1 in building C at the Georgia World Congress
Center:
- “SPK-9001: Adeno-Associated Virus Mediated Gene Transfer for
Hemophilia B – 1 Year Follow up and Impact of Baseline
Characteristics on Transgene-Derived Factor IX Activity and
Persistence” at 7 a.m. ET
- “SPK-8011: Preliminary Results from a Phase 1/2 Dose Escalation
Trial of an Investigational AAV-Mediated Gene Therapy for
Hemophilia A” at 7:45 a.m. ET
Additionally, Daniel J. Hui, Ph.D., cell-based assay lead, Spark
Therapeutics, will present a poster, “SPK-9001: Adeno-Associated
Virus Mediated Gene Transfer for Hemophilia B Achieves Sustained
Factor IX with Minimal Immune Response,” on Saturday, Dec. 9, at
5:30 p.m. ET during the “Gene Therapy and Transfer: Poster I”
session, to be held in auditorium A2, on level 1 in building A at
the Georgia World Congress Center.
Investor TeleconferenceSpark Therapeutics will
host a teleconference at 12:30 p.m. ET, on Monday, Dec. 11, 2017,
to discuss these data and address inquiries from analysts and
investors. To access a live audio webcast, please visit the
“Investors” section at www.sparktx.com, or dial (855) 851-4526
(domestic) or (720) 634-2901 (international), and enter the
passcode 8486925. Materials related to the call will be available
at the same website prior to the call.
A replay of the call will be available for one week following
the call and can be accessed by dialing (855) 859-2056 (domestic)
or (404) 537-3406 (international), and entering passcode 8486925,
or by visiting the “Investors” section at www.sparktx.com.
About Spark Therapeutics At Spark
Therapeutics, a fully integrated company committed to discovering,
developing and delivering gene therapies, we challenge the
inevitability of genetic diseases, including blindness,
hemophilia and neurodegenerative diseases. We have
successfully applied our technology directed to the retina and
liver, and currently have four programs in clinical trials or under
regulatory review, including the first potential gene therapy for a
genetic disease in the United States and product candidates that
have shown promising early results in patients with
hemophilia. At Spark, we see the path to a world where no life
is limited by genetic disease. For more information, visit
www.sparktx.com, and follow us on Twitter and LinkedIn.
Investor Contact:
Ryan Asay
Ryan.asay@sparktx.com
(215)
239-6424
Media Contact:Monique da
SilvaMonique.dasilva@sparktx.com(215) 282-7470
Onconetix (NASDAQ:ONCE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Onconetix (NASDAQ:ONCE)
Historical Stock Chart
From Sep 2023 to Sep 2024